Correction: Is the Current Management of Severe Sepsis and Septic Shock Really Evidence Based?

نویسنده

  • Jean-Louis Vincent
چکیده

The competing interests statement was incomplete and should have read: “Jean-Louis Vincent is the current chairman of the International Sepsis Forum, and a member of the steering committee of the Surviving Sepsis Campaign. His personal views do not necessarily refl ect those of the other members of these committees. The Surviving Sepsis Campaign has received funding from Eli Lilly, Baxter, and Edwards. The International Sepsis Forum is currently sponsored by bioMérieux, Biosite, Brahms Diagnostics, EBI, Eli Lilly Corporation, Eisai Global Clinical Development, GlaxoSmithKline, Novo Nordisk, Roche Diagnostics, Spectral Diagnostics, Takeda, and Toray. The author declares that he has received grants and/or honorariums from AstraZeneca, Baxter, bioMérieux, Biosite, Brahms Diagnostics, Edwards LifeSciences, Eli Lilly Corporation, Eisai Global Clinical Development, GlaxoSmithKline, Novo Nordisk, Spectral Diagnostics, Takeda, Toray, and Wyeth.”

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

بررسی موارد سپسیس و شوک سپتیک در بخش مراقبت های ویژه بیمارستان مرکز طبی کودکان

Sepsis is the systemic response to severe infection in critically ill patients. Sepsis, septic syndrome & septic shock represent the increasingly severe stages of the same disease. Despite the remarkable improvements in outcome, sepsis & septic shock remain an important cause of morbidity & mortality in children. This is a retrospective study among the patients who were admitted in the pediatri...

متن کامل

Optimal Aminoglycoside Therapy Following the Sepsis: How Much Is Too Much?

Severe sepsis and septic shock are major problems as the result of high rates morbidity andmortality in intensive care units (ICUs). In the presence of septic shock, each hour of delay inthe administration of effective antibiotics is associated with a measurable increase in mortality.Aminoglycosides are effective broad-spectrum antibiotics that are commonly used in ICUs forthe treatment of life...

متن کامل

Optimal Aminoglycoside Therapy Following the Sepsis: How Much Is Too Much?

Severe sepsis and septic shock are major problems as the result of high rates morbidity andmortality in intensive care units (ICUs). In the presence of septic shock, each hour of delay inthe administration of effective antibiotics is associated with a measurable increase in mortality.Aminoglycosides are effective broad-spectrum antibiotics that are commonly used in ICUs forthe treatment of life...

متن کامل

The management of severe sepsis and septic shock.

The diagnosis and management of severe sepsis and septic shock is a complex and dynamic process. Newer evidence-based interventions are constantly being developed and implemented with the purpose of improving morbidity and mortality. Current investigations are being performed in hospital environments to determine the change in behaviors and clinical impact with the most recent recommendations. ...

متن کامل

How I manage haematology patients with septic shock.

Patients with a variety of haematological conditions are at risk of infection and its most serious complication: septic shock. Mortality for septic shock remains high and especially so in patients with haematological malignancy and following bone marrow transplantation. However, advances in the treatment of severe sepsis have improved mortality rates even though evidence for the management of s...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • PLoS Medicine

دوره 3  شماره 

صفحات  -

تاریخ انتشار 2006